Tocilizumab-anoh
Product Images NDC 72606-050

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Tocilizumab-anoh (NDC 72606-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celltrion Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tocilizumab 01)

A line graph depicting the percentage of ACR20 responders over 24 weeks for Tocilizumab-anoh treatment groups compared to placebo. The vertical axis shows the percentage with standard error bars, and the horizontal axis shows visit weeks. Three lines represent Placebo + MTX, Tocilizumab 8 mg/kg + MTX, and Tocilizumab 4 mg/kg + MTX treatment groups, illustrating ACR20 response trends over time.*

FDA Label Image

Figure 2 (Tocilizumab 02)

A forest plot comparing risk differences in deaths (%) among studies evaluating Tocilizumab plus standard of care (SOC) versus SOC alone. The studies include COVACTA, EMPACTA, REMDACTA, and RECOVERY with overall risk difference presented on the x-axis. The plot shows individual and overall risk differences with confidence intervals for each study.*

FDA Label Image

Figure A (Tocilizumab 03)

An instructional diagram showing a syringe before and after use. The 'Before Use' syringe includes labeled parts: plunger, white finger flange, viewing window with medicine inside, needle guard, needle, and cap. The 'After Use' syringe shows the plunger depressed, medicine replaced by the needle inside the needle guard, with the cap removed.*

FDA Label Image

Figure B (Tocilizumab 04)

An instructional diagram showing items included with Tocilizumab-anoh prefilled syringe packaging: a carton, a cotton ball or gauze with an alcohol swab, an adhesive bandage, and an FDA-cleared sharps disposal container.*

FDA Label Image

Figure C (Tocilizumab 05)

An illustrated diagram showing a rectangular product package with a magnified view highlighting the expiration date format as EXP: YYYY/MM.*

FDA Label Image

Figure D (Tocilizumab 06)

An instructional diagram showing a syringe with a zoomed-in view highlighting the location of the expiration date label, formatted as EXP: YYYY/MM.*

FDA Label Image

Figure E (Tocilizumab 07)

An instructional illustration showing a syringe with an orange plunger and a white clip or holder. Above the syringe is a clock icon indicating a 30-minute duration, suggesting a timing or waiting period related to the syringe usage.*

FDA Label Image

Figure F (Tocilizumab 08)

An instructional illustration showing a detailed depiction of a syringe-like device with an emphasis on the internal needle tip through a magnified circular inset. The diagram appears to demonstrate a feature or component of the injection mechanism, related to Tocilizumab-anoh by CELLTRION USA, Inc.*

FDA Label Image

Figure G (Tocilizumab 09)

An instructional illustration showing two hands being washed under a running faucet. The image depicts hand hygiene, with water flowing from a tap onto the hands positioned under the stream.*

FDA Label Image

Figure H (Tocilizumab 10)

An instructional diagram showing injection site options on a human body for Tocilizumab-anoh. Dark gray areas on the upper arms are labeled 'Caregiver only,' while white areas on the abdomen and thighs are labeled for 'Self-injection or Caregiver.' The diagram differentiates between caregiver-administered and self-administered injection sites.*

FDA Label Image

Figure I (Tocilizumab 11)

An instructional illustration showing a person seated with one hand placing a small adhesive patch on the front of their upper thigh. The image appears to demonstrate proper placement of a topical or transdermal patch on the leg.*

FDA Label Image

Figure J (Tocilizumab 12)

An instructional illustration showing hands removing a small cap from a syringe and disposing of the cap into a trash container. The image includes arrows indicating the removal motion of the cap from the syringe, likely related to preparation or disposal steps for Tocilizumab-anoh administration.*

FDA Label Image

Figure K (Tocilizumab 13)

An instructional illustration showing how to hold and inject with a syringe. The top image indicates holding the syringe at a 45-degree angle or steeper (closer to 90 degrees) is acceptable for injection. The bottom image shows an alternative acceptable angle between 45 and 90 degrees for injecting into the skin.*

FDA Label Image

Figure L (Tocilizumab 14)

An instructional illustration showing a hand holding a pre-filled syringe designed for administering Tocilizumab-anoh. The zoomed-in view highlights the syringe's plunger and stopper, with an arrow indicating the direction of use, suggesting the proper technique to push the plunger for injection.*

FDA Label Image

Figure M (Tocilizumab 15)

An instructional illustration showing a hand holding a prefilled syringe being positioned for injection into a bent arm, indicated by an arrow suggesting the direction of injection. This image relates to the administration of Tocilizumab-anoh by CELLTRION USA, Inc.*

FDA Label Image

Figure N (Tocilizumab 16)

An instructional illustration showing a hand placing a syringe into a sharps disposal container. The syringe has an orange safety cap, and the container has an open top for safe needle disposal. This image is related to safe handling or disposal of injectable products like Tocilizumab-anoh.*

FDA Label Image

Figure A (Tocilizumab 17)

An instructional illustration for Tocilizumab-anoh, showing the pre- and post-use states of an injection pen. The diagram labels parts including the body, window area, blue needle cover, orange cap, and expiration date. After use, an orange indicator appears in the window area to show "injection complete," and the blue needle cover remains locked with the needle inside.*

FDA Label Image

Figure B (Tocilizumab 18)

An instructional illustration showing items included with Tocilizumab-anoh auto-injector packaging. It depicts a carton containing the auto-injector, a cotton ball or gauze with an alcohol swab, an adhesive bandage, and an FDA-cleared sharps disposal container.*

FDA Label Image

Figure C (Tocilizumab 19)

An illustration showing the placement of the expiration date on the packaging of Tocilizumab-anoh by CELLTRION USA, Inc. The expiration date is indicated on the box as 'EXP: YYYY/MM,' highlighting where this information can be found.*

FDA Label Image

Figure D (Tocilizumab 20)

Illustration of a Tocilizumab-anoh auto-injector pen with a magnified view highlighting the expiration date format labeled as EXP.: YYYY/MM. The image shows the full pen device and the location where the expiration date is printed.*

FDA Label Image

Figure E (Tocilizumab 21)

An instructional diagram featuring a clock icon showing 45 minutes and an image of a vial or syringe with a red cap, likely indicating a preparation or wait time related to Tocilizumab-anoh by CELLTRION USA, Inc.*

FDA Label Image

Figure F (Tocilizumab 22)

An instructional illustration showing a pen-like device with a close-up inset highlighting an elongated oval window on the device's body. The bottom part of the device is shaded in orange. The image likely relates to the Tocilizumab-anoh product by CELLTRION USA, Inc.*

FDA Label Image

Figure G (Tocilizumab 23)

Illustration showing a pair of hands being washed under a running faucet. The image emphasizes proper hand hygiene with water flowing from a tap into a sink basin.*

FDA Label Image

Figure H (Tocilizumab 24)

An anatomical illustration showing areas on the human body for injection site use related to Tocilizumab-anoh. Shaded areas indicate injection sites for caregiver-only use on the upper arms, while unshaded areas on the abdomen and thighs indicate sites suitable for self-injection or caregiver administration.*

FDA Label Image

Figure I (Tocilizumab 25)

An instructional illustration showing a person seated with one hand placing or peeling a small adhesive patch on the front of their upper thigh. The image likely demonstrates the correct site or method for applying a transdermal patch or similar medication delivery system.*

FDA Label Image

Figure J (Tocilizumab 26)

An instructional illustration showing hands removing the needle cover from a syringe or pen device. The inset details proper disposal of the needle cover into a sharps container. The image emphasizes safe handling and disposal of the needle cover.*

FDA Label Image

Figure K (Tocilizumab 27)

An instructional illustration showing a hand holding a Tocilizumab-anoh prefilled injection pen positioned near a person's thigh. A magnified inset highlights the window on the injection pen, likely indicating where to observe the medication or injection status.*

FDA Label Image

Figure L (Tocilizumab 28)

Instructional illustration showing two methods of holding and injecting with a syringe at a 90-degree angle. The top shows the syringe held vertically for injection into an arm or thigh. The bottom shows the syringe held horizontally for injection into the abdomen, both demonstrating proper injection angles for Tocilizumab-anoh.*

FDA Label Image

Figure M (Tocilizumab 29)

An instructional diagram showing two sequential steps for using a pen injection device. The first step depicts pressing the device down until a click is heard, followed by a second press until a second click, with instruction to then count slowly to 5. The hand holds the pen vertically over an injection site.*

FDA Label Image

Figure N (Tocilizumab 30)

An instructional illustration showing a hand holding a syringe vertically above a patient's knee, indicating an upward motion. A close-up inset highlights a red-colored indicator inside the syringe barrel. The image likely demonstrates part of the injection or preparation process for Tocilizumab-anoh by CELLTRION USA, Inc.*

FDA Label Image

Figure O (Tocilizumab 31)

An instructional illustration showing a hand holding a test strip or similar device being inserted into a slot or opening on a container. The image depicts the proper method for placing the strip into the container, potentially for disposal or testing purposes.*

FDA Label Image

Principal Display Panel (80 mg/4 mL Vial Carton)

The packaging label for Tocilizumab-anoh Injection, 80 mg/4 mL (20 mg/mL) by CELLTRION USA, Inc. It is a single-dose vial intended for intravenous infusion after dilution. The label includes dosing instructions to see prescribing information, storage requirements at 2°C to 8°C, and contents listing active and inactive ingredients. The label also shows barcode, manufacturer and distributor information, and notes to discard unused portions.*

FDA Label Image

Principal Display Panel (200 mg/10 mL Vial Carton)

Tocilizumab-anoh Injection 200 mg/10 mL (20 mg/mL) single-dose vial carton for intravenous infusion after dilution. The label shows dosage instructions, storage conditions (2°C to 8°C, protect from light), manufacturer CELLTRION Inc., and distributor CELLTRION USA, Inc. The carton includes barcode, NDC 72606-049-01, and a list of inactive ingredients. It states to discard unused portion and that the product contains no preservatives.*

FDA Label Image

Principal Display Panel (400 mg/20 mL Vial Carton)

Packaging label for Tocilizumab-anoh Injection 400 mg/20 mL (20 mg/mL) by CELLTRION USA, Inc. The label specifies the product is for intravenous infusion after dilution, single-dose vial, with a 1 vial package. It includes storage instructions, contents detail including inactive ingredients, manufacturer and distributor addresses, and an NDC 72606-050-01 barcode.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Autoinjector Carton)

Packaging label for Tocilizumab-anoh Injection 162 mg/0.9 mL single-dose autoinjector by CELLTRION USA, Inc. The label details the dosage form as a subcutaneous injection, packaging includes one autoinjector, and emphasizes use for subcutaneous injection only. It includes manufacturer and distributor information, as well as dosage and handling instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.